These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8167635)

  • 1. [Evaluation criteria for uveitis in Behçet's syndrome].
    Hamza M; Ouertani A
    Rev Rhum Ed Fr; 1993 Apr; 60(4):315-6. PubMed ID: 8167635
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ocular prognosis in Behçet's disease].
    Cochereau-Massin I; Wechsler B; Le Hoang P; Le Thi Huong Du; Girard B; Rousselie F; Godeau P
    J Fr Ophtalmol; 1992; 15(5):343-7. PubMed ID: 1430813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uveitis in juvenile Behçet's disease: clinical course and visual outcome compared with adult patients.
    Kramer M; Amer R; Mukamel M; Snir M; Jaouni T; Friling R
    Eye (Lond); 2009 Nov; 23(11):2034-41. PubMed ID: 19151650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjunctival ulcers in Behçet's disease.
    Zamir E; Bodaghi B; Tugal-Tutkun I; See RF; Charlotte F; Wang RC; Wechsler B; LeHoang P; Anteby I; Rao NA
    Ophthalmology; 2003 Jun; 110(6):1137-41. PubMed ID: 12799237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment.
    Yamada Y; Sugita S; Tanaka H; Kamoi K; Takase H; Mochizuki M
    Br J Ophthalmol; 2011 Feb; 95(2):205-8. PubMed ID: 20542984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN.
    Kotter I; Deuter C; Stubiger N; Zierhut M
    J Rheumatol; 2005 Aug; 32(8):1633; author reply 1634. PubMed ID: 16078350
    [No Abstract]   [Full Text] [Related]  

  • 7. [Infliximab treatment for Behçet's disease--beginning of the biological drug era].
    Namba K
    Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):85-6. PubMed ID: 20187504
    [No Abstract]   [Full Text] [Related]  

  • 8. [Value and complications of immunosuppressive therapy in uveitis of Behcet's disease or of other etiology. Apropos of 40 cases].
    Niessen F; Campinchi R; Bloch-Michel E
    J Fr Ophtalmol; 1982; 5(6-7):407-16. PubMed ID: 7130629
    [No Abstract]   [Full Text] [Related]  

  • 9. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet's disease.
    Rosenbaum JT
    J Rheumatol; 2004 Jul; 31(7):1241-3. PubMed ID: 15229938
    [No Abstract]   [Full Text] [Related]  

  • 10. [Bolus of cyclophosphamide and methylprednisolone in uveitis in Behçet's disease. Preliminary results with the use of new criteria of evaluation].
    Hamza M; Meddeb S; Mili I; Ouertani A
    Ann Med Interne (Paris); 1992; 143(7):438-41. PubMed ID: 1300863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasculitis in Behçet's syndrome: evidence-based review.
    Reynolds N
    Curr Opin Rheumatol; 2008 May; 20(3):347-52. PubMed ID: 18388529
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prognostic factors of ocular involvement in Behçet's disease].
    Belkhadir K; Boutimzine N; Laghmari M; Amazouzi A; Tachfouti S; Cherkaoui O
    J Fr Ophtalmol; 2019 Jun; 42(6):612-617. PubMed ID: 31088739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cyclosporin A in the treatment of uveitis in Behçet's disease: apropos of a case].
    Annonier P; Brini A
    Bull Soc Ophtalmol Fr; 1986 Mar; 86(3):305-8. PubMed ID: 3802341
    [No Abstract]   [Full Text] [Related]  

  • 14. [Epidemiology and the present status of Behcet's syndrome].
    Araki Y
    Saishin Igaku; 1971 Mar; 26(3):458-64. PubMed ID: 5547388
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis.
    Mochizuki M; Masuda K; Sakane T; Inaba G; Ito K; Kogure M; Sugino N; Usui M; Mizushima Y; Ohno S
    Transplant Proc; 1991 Dec; 23(6):3343-6. PubMed ID: 1721456
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of ocular manifestations of Behçet's disease.
    Davatchi F
    Adv Exp Med Biol; 2003; 528():487-91. PubMed ID: 12918750
    [No Abstract]   [Full Text] [Related]  

  • 18. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
    Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of infliximab on refractory uveitis in Behcet's disease.
    Sayarlioglu M; Cinal A; Topcu N; Demirok A
    Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pars planitis and Behçet's syndrome].
    Ardouin M; Urvoy M; Perraut JP
    Bull Soc Ophtalmol Fr; 1978 Dec; 78(12):931-3. PubMed ID: 755579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.